Wachovia Starts Bioenvision (BIVN) at Market Perform
BIVN Hot Sheet
Rating Summary:0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Wachovia initiates coverage on Bioenvision Inc. (Nasdaq: BIVN) with a Market Perform rating and $5.60-$7 valuation range. The firm said the outcome of the shareholder vote on the merger with Genzyme (Nasdaq: GENZ) is uncertain.
You May Also Be Interested In
- UPDATE: William Blair Starts EPIQ Systems (EPIQ) at Outperform; Broad Suite of Solutions in Electronic Discovery Sector
- UBS Maintains a 'Neutral' on VeriFone (PAY); Europe Demand Healthy, but FX Emerges as Headwind
- Wunderlich Securities Starts Beacon Roofing Supply (BECN) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
